Nasopharyngeal Carcinoma
Conditions
Keywords
COX-2 inhibitors, radiosensitivity, nasopharyngeal carcinoma
Brief summary
The purpose of this study is to determine whether celecoxib is effective in the treatment of nasopharyngeal carcinoma by concurrent chemoradiation with weekly nedaplatin.
Detailed description
1. Study Patients: Patients are all recruited from the Third Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China. All the patients provide written informed consent before enrollment. All eligible patients received a pretreatment evaluation including complete history and physical examination, endoscopic biopsy, routine laboratory tests for hematologic, renal and hepatic function as well as a dental and nutritional evaluation prior to treatment. Radiological investigations consisted of computed tomography (CT) scan or magnetic MRI of the nasopharynx, chest radiography, ultrasound of the upper abdomen and bone scintigraphy. Pathologic confirmation of nasopharyngeal cancer (NPC) was performed and re-classified according to the world health organization (WHO) subtypes. 2. Study design: A total of 120 NPC patients are randomly and equally divided into two groups: Nedaplatin alone concurrent radiotherapy, Celecoxib plus nedaplatin concurrent radiotherapy. The tumor response will be evaluated by magnetic resonance imaging (MRI) after 4 weeks. The tumor responses including Complete Response (CR), Partial Response (PR) , Stable Disease (SD) and Progressive Disease (PD) is defined according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0. The show term or long term toxicity will be evaluated according to the National Cancer Institute Common Toxicity Criteria (NCICTC), version 3.0. All the NPC patients are requested to be followed up with an expected average of every 3 months after the therapy.The other clinical outcomes including the first evidence of cancer progression or death from any cause, the occurrence of distant metastasis, and the relapse of a local or nodal tumor will be evaluated as well. The follow-up will be up to 2018. 3. Statistical Analysis: Statistical Package for the Social Sciences (SPSS 13.0) is used to analyze the effect of celecoxib on the nedaplatin concurrent radiotherapy. Cox's regression model and Kaplan-Meier method is used to conduct survival analysis. Clinical outcomes including the tumor responses, 1-year/3-year/5-year overall survival (OS), progression free survival (PFS), distant metastasis failure-free survival (DMFS) and locoregional failure-free survival (LFFS) will be analyzed. The multivariate Cox's regression model is used to adjust the confounders, including age and body mass index. P value less than 0.05 will be considered to be statistically significant.
Interventions
DRUGCelecoxib
Celecoxib 200mg bid po, to the end of concurrent radiotherapy
DRUGNedaplatin
40 mg/m2, IV (in the vein) on day 1 of each 7 day cycle. Number of Cycles: to the end of concurrent radiotherapy
RADIATIONConcurrent Radiotherapy
The standard radiotherapy schedules were available as conventional radiotherapy and Intensity Modulated Radiotherapy (IMRT). The cumulative radiation dose was 68\ 74 Gy for primary tumor (2.0\ 2.3 Gy/f/day, 5 day/ week, /6\ 7 weeks), and 50\ 54 Gy for lymphatic positive area (1.8 \ 2 Gy/f/day, 5 day/week, /5.0\ 5.5 weeks).
Sponsors
Changjie Huang
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Patients with NPC newly diagnosed by histopathology, and without radiotherapy or chemotherapy before the clinical trial * Patients with measurable lesions by Response Evaluation Criteria in Solid Tumors (RECIST) criteria * With the Eastern Cooperative Oncology Group Performance Status (ECOG PS) as 0-1 score * Serum hemoglobin ≥10gm/dL, platelet ≥100000/μL, neutrophil granulocyte absolute counting is 1500/μL * Serum creatinine ≤1.25 times of upper normal limit (UNL), creatinine clearance rate ≥ 60 ml/min * Serum bilirubin ≤ 1.5times of UNL, serum aspartate aminotransferase (AST) or glutamic-oxaloacetic transaminase(GOT)≤ 2.5 times of UNL, serum alanine aminotransferase (ALT) or glutamic-pyruvic transaminase (GPT) ≤ 2.5 times of UNL, alkaline phosphatase≤5 times of UNL * The estimate overall survival (OS)\> 6 months * With formal informed consent forms signed.
Exclusion criteria
* With symptomatic brain/bone metastases, * With cognitive impairment or other malignancies * With any contraindications for radiotherapy and chemotherapy (such as active phase of infection, myocardial infarction within 6 months, symptomatic heart disease, including unstable angina pectoris, congestive heart failure or uncontrolled arrhythmias, in current immunosuppressive therapy) * Current pregnancy, lactating women or women with fertility but don't take contraceptive measures yet * With severe bone marrow dysfunction * With bleeding tendency * With abuse of drugs or alcohol addicts * Who may have III-IV type of allergic reactions to any treatment in this study * With termination of trial because of intolerable toxicity, other study drugs using during the clinical study, or unwilling to continue the treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with different tumor response and short term toxicity will be recorded | Patients are asked to be followed within an expected average of 4 weeks after therapy | The tumor responses including Complete Response (CR), Partial Response (PR) , Stable Disease (SD) and Progressive Disease (PD) were evaluated by MRI, according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0; Short term toxicity was evaluated according to the National Cancer Institute Common Toxicity Criteria (NCICTC), version 3.0. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The date when each patient shows the first evidence of cancer progression or death from any cause will be recorded. | Patients will be asked to be followed in an expected average of every 3 months after therapy. From date of treatment initiation until the date of first documented progression or date of death from any cause, whichever comes first, up to 36 months | Progression free survival (PFS) is defined as the time between treatment initiation and the first evidence of cancer progression or death from any cause. |
| The date when each patient presents the occurrence of distant metastasis will be recorded. | Patients will be asked to be followed in an expected average of every 3 months after therapy. From date of treatment initiation until the date of first documented occurrence of distant metastasis, assessed up to 36 months | Distant metastasis failure-free survival (DMFS) is defined as the time between treatment initiation and the occurrence of distant metastasis. |
| The date when each patient presents the relapse of a local or nodal tumor will be recorded. | Patients will be asked to be followed in an expected average of every 3 months after therapy. From date of treatment initiation until the date of first documented relapse of a local or nodal tumor, whichever came first, assessed up to 36 months. | Locoregional failure-free survival (LFFS) is defined as the time between treatment initiation and the relapse of a local or nodal tumor. |
| The date when each patient is dead will be recorded. | Patients will be asked to be followed in an expected average of every 3 months after therapy. From date of treatment initiation until the date of first documented death from any cause, assessed up to 36 months. | Overall survival (OS) is defined as the time between treatment initiation and the patient death. |
| Age will be recorded when the therapy starts | Patients are asked to provide the birthday before the start of therapy | Age is defined as the time between the birthday and treatment initiation. |
| Height in meters and weight in kilograms will be recorded when therapy starts | Patients are asked to be measured the height and weight before the start of therapy | High and weight are measured in standing posture without shoes by trained nurses. Body mass index is calculated form weight in kilograms divided by height in meters squared. |
| Long term toxicity will be recorded as the Number of Participants with Treatment-Related Adverse Events | Patients will be asked to be followed in an expected average of every 3 months after therapy. From date of treatment initiation until the documented date of the Treatment-Related Adverse Events, whichever comes first, assessed up to 36 months. | The Treatment-Related Adverse Events are assessed by the National Cancer Institute Common Toxicity Criteria (NCICTC), version 3.0. |
Countries
China
Contacts
Primary ContactYan Mao, M.D.
Outcome results
None listed